The TCGA study revealed that other than the PEAR1-NTRK1 fusion, which has been detected in patients with breast cancer and sarcoma [17,18], NTRK fusions identified in esophageal and gastric cancers are not common mutations. Here, PEAR1 is linked to breast carcinoma.